成人创伤急性大出血患者全血输血与成分输血比较
该系统评价于2019年12月15日检索文献,比较成人创伤急性大出血患者全血输血与成分输血及30天死亡率。共纳入6项研究、3255例患者。报告30天死亡率的3项研究中仅1项显示全血与成分输血有统计学显著差异,2项无统计学差异;2项报告院内死亡率的回顾性研究未校正死亡率无统计学差异,但 logistic 回归分析均显示全血输血策略者死亡可能性更低。作者承认证据质量差且纳入试验有限,结论为不支持也不反对全血输血。
要点
- 系统评价纳入6项研究共3255例成人创伤急性大出血患者,比较全血输血与成分输血。
- 报告30天死亡率的3项研究中,仅1项显示全血与成分输血有统计学显著差异,2项无统计学差异。
- 2项回顾性研究报告院内未校正死亡率无统计学差异,但 logistic 回归分析均显示全血输血策略者死亡可能性更低。
- 证据质量:1项随机对照试验为中等证据,2项回顾性研究分别为低和极低证据。
- 作者结论:因证据质量差且纳入试验有限,该系统评价不支持也不反对使用全血输血。
适用人群与场景
- 成人创伤急性大出血患者。
- 排除未报告死亡率的研究。
研究设计与关键结果
- 研究类型:系统评价,检索于2019年12月15日进行,最终纳入6项研究、3255例患者。
- 报告30天死亡率的3项研究包括1项随机对照试验(中等证据)和2项回顾性研究(分别为低和极低证据),仅1项显示全血与成分输血有统计学显著差异,2项无统计学差异。
- 2项报告院内死亡率的回顾性研究未校正死亡率无统计学差异,但 logistic 回归分析均显示全血输血策略者死亡可能性更低。
证据类型、等级与局限
- 证据类型:系统评价,采用 Cochrane 偏倚风险工具评价方法学质量,并使用 GRADE 方法评级。
- 纳入研究中1项随机对照试验为中等证据,2项回顾性研究分别为低和极低证据。
- 局限:原文报告局限性包括证据质量差和纳入试验数量有限。
对床旁实践的改变
- 该系统评价未提供证据支持或反对成人创伤急性大出血使用全血输血替代成分输血。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: In the era of damage control resuscitation of trauma patients with acute major haemorrhage, transfusion practice has evolved to blood component (component therapy) administered in a ratio that closely approximates whole blood (WB). However, there is a paucity of evidence supporting the optimal transfusion strategy in these patients. The primary objective was therefore to establish if there is an improvement in survival at 30 days with the use of WB transfusion compared with blood component therapy in adult trauma patients with acute major haemorrhage.
METHODOLOGY: A systematic literature search was performed on 15 December 2019 to identify studies comparing WB transfusion with component therapy in adult trauma patients and mortality at 30 days. Studies which did not report mortality were excluded. Methodological quality of included studies was interpreted using the Cochrane risk of bias tool, and rated using the Grading of Recommendations Assessment, Development and Evaluation approach.
RESULTS: Search of the databases identified 1885 records, and six studies met the inclusion criteria involving 3255 patients. Of the three studies reporting 30-day mortality (one randomised controlled trial (moderate evidence) and two retrospective (low and very low evidence, respectively)), only one study demonstrated a statistically significant difference between WB and component therapy, and two found no statistical difference. Two retrospective studies reporting in-hospital mortality found no statistical difference in unadjusted mortality, but both reported statistically significant logistic regression analyses demonstrating that those with a WB transfusion strategy were less likely to die.
CONCLUSION: Recognising the limitations of this systematic review relating to the poor-quality evidence and limited number of included trials, it does not provide evidence to support or reject use of WB transfusion compared with component therapy for adult trauma patients with acute major haemorrhage.
PROSPERO REGISTRATION NUMBER: CRD42019131406.
参考来源
- Avery P, Morton S, Tucker H, et al. Whole blood transfusion versus component therapy in adult trauma patients with acute major haemorrhage. Emerg Med J. 2020. PMID: 32376677. doi:10.1136/emermed-2019-209040
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。